Discovery of tankyrase scaffolding inhibitor specifically targeting the ARC4 peptide binding domain
Structure · 2026
DOI: 10.1016/j.str.2025.12.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Structure, 2026. Verfasst von Chiara Bosetti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, 90220 Oulu, Finland. Hauptthemen laut MEDLINE: Tankyrases, Enzyme Inhibitors. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway, Helse Sør-Øst RHF, European Commission.
Abstract (Originalsprache)
Tankyrases are poly-ADP-ribosyltransferases that orchestrate numerous biological processes involved in disease. Their established regulatory roles, particularly within the WNT/β-catenin pathway, have driven notable drug discovery efforts aimed at inhibiting their catalytic activity. Targeting tankyrases' interaction with proteins through their ARC domains represents an alternative strategy to be explored as a therapeutic approach against specific protein-protein interactions. In this article, we employed a pre-established FRET-based assay to screen the EU-OPENSCREEN libraries for identification of ARC4 inhibitors. We discovered a series of pyrrolone-based compounds, and we synthesized compound S8 (ARCher-142), which binds selectively to ARC4 with a potency of 8 μM. NMR analysis and X-ray crystallography allowed us to identify the binding site and to rationalize the observed selectivity. Despite binding exclusively to ARC4, the inhibitor can attenuate the WNT/β-catenin signaling pathway in cells. Our work demonstrates that targeting single ARC domains is possible, offering an inhibition approach tailored to tankyrase ARC4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, 90220 Oulu, Finland.
- Norwegian Centre for Molecular Biosciences and Medicine, University of Oslo, 0349 Oslo, Norway.
- Department of Chemistry, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
- Department of Immunology, Oslo University Hospital, 0372 Oslo, Norway; Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, 0372 Oslo, Norway.
- Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, 90220 Oulu, Finland. Electronic address: lari.lehtio@oulu.fi.
Förderung
- Research Council of Norway
- Helse Sør-Øst RHF
- European Commission
- Carlsberg Foundation
- Novo Nordisk Fonden
- NoVo Foundation
- Horizon Europe
- Jane ja Aatos Erkon Säätiö
Zitieren
APA
Bosetti, C., Galera-Prat, A., Sowa, S. T., Gade, A., Braga, C., Brinch, S. A., Nami, F., Pääkkönen, J., Pulju, V., Meling, M. T., Candamo-Lourido, M., Waaler, J., Clausen, M. H., & Lehtiö, L. (2026). Discovery of tankyrase scaffolding inhibitor specifically targeting the ARC4 peptide binding domain. Structure. https://doi.org/10.1016/j.str.2025.12.015
Vancouver
Bosetti C, Galera-Prat A, Sowa ST, Gade A, Braga C, Brinch SA, et al. Discovery of tankyrase scaffolding inhibitor specifically targeting the ARC4 peptide binding domain. Structure. 2026. doi:10.1016/j.str.2025.12.015
BibTeX
@article{Bosetti2026,
author = {Bosetti, Chiara and Galera-Prat, Albert and Sowa, Sven T and Gade, Alexandra and Braga, Cláudia and Brinch, Shoshy A and Nami, Faranak and Pääkkönen, Johan and Pulju, Veeti and Meling, Maureen T and Candamo-Lourido, Maria and Waaler, Jo and Clausen, Mads H and Lehtiö, Lari},
title = {Discovery of tankyrase scaffolding inhibitor specifically targeting the ARC4 peptide binding domain},
journal = {Structure},
year = {2026},
doi = {10.1016/j.str.2025.12.015}
}
EUVIMED